Pasar al contenido principal

BIOQUIMICA DE LA PROTEOLISIS: FUNCION, REGULACION Y ESTRUCTURA DE PEPTIDASAS DE RELEVANCIA BIOMEDICA O BIOTECNOLOGICA Y DE SUS INHIBIDORES

PRE2020-096731

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biochemical and structural characterization of the human gut microbiome metallopeptidase IgAse provides insight into its unique specificity for the Fab' region of IgA1 and IgA2

  • Ramírez-Larrota, Juan Sebastián
  • Juyoux, Pauline
  • Guerra, Pablo
  • Eckhard, Ulrich
  • Gomis-Rüth, F. Xavier
Human immunoglobulin A (IgA), comprising the isotypes IgA1 and IgA2, protects ~400 m2 of mucosal surfaces against microbial infections but can also lead to aberrant IgA deposits that cause disease. Certain bacteria have evolved peptidases that cleave the hinge between the Fab and Fc fragments of IgA, undermining its immune function. These peptidases specifically target IgA1, but not IgA2, which predominates in the gut and possesses a structurally distinct hinge region. The only known IgA2-specific peptidase is IgAse from the gut microbiome member Thomasclavelia ramosa, which also targets IgA1 but no other proteins. IgAse is a ~ 140-kDa, seven-domain, membrane-bound metallopeptidase (MP). Differential scanning fluorimetry, small-angle X-ray scattering, AI-based structural predictions, mass spectrometry, and high-resolution crystallography and cryo-electron microscopy of multidomain fragments of IgAse revealed a novel 313-residue catalytic domain (CD) from the igalysin family within the metzincin MP clan. The CD is flanked by an N-terminal globular C-type lectin-like domain and a wrapping domain (WD), followed by four all-β domains. Functional studies involving a comprehensive set of constructs (wild-type and mutant), authentic and recombinant IgA fragments, and inhibitors demonstrated that the minimal functional assembly requires the CD and WD, along with the Fab and hinge region (Fab’). Modelling studies suggested that the Fab heavy-chain constant domain interacts with the N-terminal subdomain of the CD, positioning the hinge peptide for cleavage–a mechanism confirmed by mutational analysis. These findings open avenues for therapeutic strategies to inhibit the only known IgA1/IgA2 peptidase and to develop it for dissolving pathologic IgA deposits., This study was supported in part by funding from public bodies, which included grants from the State Plan for Scientific and Technical Research and Innovation (AEI; MCIN/AEI/10.13039/501100011033) to F.X.G.R. (PDC2022-133344-I00 and PID2022- 137827OB-I00), to U.E. (RYC2020-029773-I, PID2021-128682OA-I00, and CNS2024- 154537), and to J.S.R.L (PRE2020-096731). This study was funded by the European Union Next Generation EU/PRTR and cofunded by the ERDF – A way of making Europe. Further funding was provided by the AGAUR-program of the Government of Catalonia to F.X.G.R and U.E. (2021SGR00423) and by grant IU16-014045 (CRYO-TEM) from the Government of Catalonia to P.G. The purchase of the CM02 microscope was funded by the EquipEx+ France Cryo-EM project (ANR-21-ESRE-0046) from the Agence Nationale de la Recherche to P.J., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted enzymatic therapy for coeliac disease

  • Girbal-González, Marina
  • Rodríguez-Banqueri, Arturo
  • Swaid, Hadeel
  • Mendes, Soraia R.
  • Garzón-Flores, Laura
  • Ramírez-Larrota, Juan Sebastián
  • Cueva, Carolina
  • Moreno-Arribas, M. Victoria
  • Regl, Christof
  • Huber, Christian G.
  • Scherf, Katharina A.
  • Rodríguez-Lagunas, María José
  • Franch-Masferrer, Àngels
  • Eckhard, Ulrich
  • Pérez-Cano, Francisco J.
  • Gomis-Rüth, F. Xavier
[Data availability] The coordinates of the experimental celiacase structure determined in this study are retrievable from the Protein Data Bank at www.pdb.org under access code 9QR8. The proteomics datasets are retrievable from Zenodo (https://zenodo.org/records/19456489)., The source data of this paper are collected in the following database record: biostudies:S-SCDT-10_1038-S44321-026-00430-8., Coeliac disease (CD) is an autoimmune enteropathy triggered by proline-rich gluten immunogenic peptides (GIPs), for which no curative therapy exists. We developed celiacase (Clc), a recombinant prolyl endopeptidase engineered from pitcher plant neprosin to enhance expression, stability, and activity. Clc showed maximal activity at gastric pH, synergized with and resisted pepsin, and efficiently cleaved GIPs, including the highly immunogenic 33-mer, outperforming Aspergillus niger prolyl endopeptidase in degrading GIPs from wheat flour and gliadin. At an enzyme-to-gliadin ratio of 1:250, Clc reduced GIP levels by up to 99% in a dynamic human gastrointestinal simulator. Ex vivo, Clc-digested 33-mer fragments failed to elicit cytokine responses in mouse and rat macrophages and duodenal biopsies from CD patients. In vivo, low-dose Clc (1:75-1:380) degraded gliadin and attenuated pathology in gliadin-fed mice, reducing villus atrophy, inflammation, antibody responses, and gluten-induced dysbiosis, while restoring immune-regulatory markers and microbial metabolic pathways. In summary, Clc is a potent, acid-stable glutenase with promise as a therapeutic adjunct or alternative to a gluten-free diet for CD patients., This study was supported in part by funding from public and private bodies, which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MCIN/AEI/10.13039/501100011033: PDC2022-133344-I00, PID2022-137827OB-I00, PID2025-171123OB-I00 (FXG-R); RYC2020-029773-I, PID2021-128682OA-I00, PID2024-159901OB-I00, CNS2024-154537 (UE); PRE2020-096731 (JSR-L); PRE2022-000841 (HS); CEX2021-001234-M “María de Maeztu” Unit of Excellence Award (FJP-C). “Vicente Varea 2025” Grant (FJP-C)—Celiac Association of Catalonia. PREDOCS-UB Predoctoral Contract University of Barcelona (2022 call) (MG). Agency for Management of University and Research Grants (AGAUR), Government of Catalonia grant 2021SGR00423 (UE; FXG-R). CONEXIÓN TRIGO Network—Higher Scientific Research Council (CSIC)., With funding from the Spanish government through the "Unit of Excellence Maria de Maeztu" accreditation (CEX2021-001234-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The protease code of the bacterial gut microbiota: ecological regulation, barrier disruption, and rewiring host defense and signaling

  • Eckhard, Ulrich
  • Ramírez-Larrota, Juan Sebastián
  • Estevan-Morió, Eva
  • Gomis-Rüth, F. Xavier
The human gastrointestinal tract is home to a dense and diverse microbial ecosystem that functions as a complex superorganism. Yet, the enzymatic machinery responsible for orchestrating this coexistence remains underexplored. Among these enzymes, microbial peptidases (proteases) represent pivotal effectors of the host-microbe interface. Far from acting merely as nonspecific digestive degraders, these proteases serve as highly specific signaling enzymes that can tip the balance between eubiosis and dysbiosis, functioning as critical architects of biofilm structure while also acting as potent virulence factors. This review provides a focused analysis of the microbial proteolytic landscape. We first examine how these enzymes govern community dynamics through the remodeling of biofilm protein matrices and the quenching of peptide-based quorum sensing. At the host-microbe boundary, we detail the hierarchical dismantling of barriers: from mucinases that compromise the protective mucus layer, to the systematic cleavage of adherens junctions by key effectors including enterotoxigenic Bacteroides fragilis toxin, Campylobacter jejuni HtrA, and Porphyromonas gingivalis gingipains. Finally, we explore how proteases transcend physical destruction to manipulate cellular signaling, subverting mucosal immunity via immunoglobulin A cleavage and driving inflammation through the activation of protease-activated receptors., This work was supported by the Spanish Ministry of Science and Innovation (MCIN) and the State Research Agency (AEI) (DOI: 10.13039/501100011033) through grants RYC2020-029773-I, PID2021-128682OA-I00, PID2024-159901OB-I00, and CNS2024-154537 to U.E.; PRE2020-096731 to J.S.R.L.; FPU23/02649 to E.E.M; and PDC2022-133344-I00, PID2025-171123OB-I00, and PID2022-137827OB-I00 to F.X.G.R. These grants were co-funded by the European Union NextGenerationEU/PRTR and the European Regional Development Fund (ERDF) “A way of making Europe”. Additional support was provided by the Government of Catalonia (AGAUR) under grant 2021SGR00423 to U.E. and F.X.G.R., Peer reviewed